Gainers

• Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million.
• Pulmonx (NASDAQ:LUNG) stock increased by 10.6% to $2.19. The company's market cap stands at $83.7 million. The company's, Q3 earnings came out today.
• NextCure (NASDAQ:NXTC) shares moved upwards by 8.48% to $6.2. The company's market cap stands at $23.9 million.
• Adagio Medical Holdings (NASDAQ:ADGM) stock increased by 7.3% to $0.11. The market value of their outstanding shares is at $2.6 million.
• Circle8 Group (NASDAQ:CIRC) shares increased by 7.28% to $0.25. The market value of their outstanding shares is at $28.4 million.
• OrthoPediatrics (NASDAQ:KIDS) stock increased by 7.05% to $25.5. The market value of their outstanding shares is at $627.1 million. As per the news, the Q3 earnings report came out today.

Losers

• Rapport Therapeutics (NASDAQ:RAPP) shares decreased by 21.0% to $21.76 during Tuesday's after-market session. The company's market cap stands at $1.2 billion.
• Beta Bionics (NASDAQ:BBNX) stock declined by 13.24% to $18.56. The company's market cap stands at $1.1 billion. The company's, Q3 earnings came out today.
• Karyopharm Therapeutics (NASDAQ:KPTI) shares decreased by 9.59% to $0.43. The market value of their outstanding shares is at $10.9 million.
• Pluri (NASDAQ:PLUR) shares declined by 8.41% to $1.09. The market value of their outstanding shares is at $14.1 million.
• Werewolf Therapeutics (NASDAQ:HOWL) stock declined by 8.2% to $0.95. The company's market cap stands at $47.6 million.
• Beyond Air (NASDAQ:XAIR) shares declined by 7.7% to $2.04. The market value of their outstanding shares is at $2.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.